Claims for Patent: 5,039,705

Summary for Patent: 5,039,705

Title:	Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
Abstract:	This invention concerns anti-hypertensive compositions and a method of lowering blood pressure in mammals. The active component of the compositions is a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are independently chosen from straight chain and branched chain C.sub.1 -C.sub.12 alkyl groups and benzyl, with the proviso that no branch occur on the alpha carbon atom of the alkyl groups; or R.sub.1 and R.sub.2 together with the nitrogen atom they are bonded to form a pyrrolidino, piperidino, piperazino or morpholino group, M.sup.+ is a pharmaceutically acceptable cation, wherein X is the valence of the cation.
Inventor(s):	Keefer; Larry K. (Bethesda, MD), Wink; David A. (Frederick, MD), Dunams; Tambra M. (Frederick, MD), Hrabie; Joseph A. (Frederick, MD)
Assignee:	The United States of America as represented by the Department of Health (Washington, DC)
Application Number:	07/409,552
Patent Claims:	1. A sterile pharmaceutical composition useful in the treatment of hypertension comprising: an effective amount of a compound of the formula ##STR5## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of a straight chain or branched chain C.sub.1 -C.sub.12 alkyl group and a benzyl group, with the proviso that no branch occur on the alpha carbon atom, M.sup.+X is a pharmaceutically acceptable cation, wherein x is the valence of the cation; and a pharmaceutically acceptable carrier therefor. 2. The composition of claim 1 in a form suitable for injection. 3. The composition of claim 2 wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of C.sub.2 -C.sub.6 alkyl groups. 4. The composition of claim 3 wherein M.sup.+X is selected from the group consisting of group I, group II ions and NR.sub.3 R.sub.4 R.sub.5 R.sub.6.sup.+, wherein R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are independently selected from the group consisting of H, C.sub.1 -C.sub.12 alkyl, C.sub.3 -C.sub.7 cycloalkyl and benzy. 5. The composition of claim 4 wherein R.sub.1 and R.sub.2 are ethyl. 6. The composition of claim 5 wherein M.sup.+X is Na.sup.+, K.sup.+, Ca.sup.+2 or N(C.sub.2 H.sub.5).sub.2 H.sub.2.sup.+. 7. The composition of claim 2, 3, 4, 5 or 6 wherein the pharmaceutically acceptable carrier is selected from the group consisting of sterile water, phosphate buffered saline and aqueous glucose solutions. 8. The pharmaceutical composition of claim 1, wherein said composition is a sterile composition suitable for intravenous injection. 9. The pharmaceutical composition of claim 8, wherein said composition further comprises an antioxidant. 10. A method of treating hypertension in mammals which comprises administering to a mammal, in need thereof, a blood pressure lowering effective amount of a compound of the formula: ##STR6## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of a straight chain or branched chain C.sub.1 -C.sub.12 alkyl group and a benzyl group, with the proviso that no branch occur on the alpha carbon atom; and M.sup.+X is a pharmaceutically acceptable cation, wherein x is the valence of the cation. 11. The method of claim 16 wherein R.sub.1 and R.sub.2 are independently selected from C.sub.2 -C.sub.6 alkyl groups. 12. The method of claim 11 wherein M.sup.+X is selected from the group consisting of group I, group II ions and NR.sub.3 R.sub.4 R.sub.5 R.sub.6.sup.+, wherein R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are independently selected from H, C.sub.1 -C.sub.12 alkyl groups, C.sub.3 -C.sub.7 cycloalkyl or benzyl. 13. The method of claim 12 wherein R.sub.1 and R.sub.2 are ethyl. 14. The method of claim 13 wherein M.sup.+X is NA.sup.+, K.sup.+, Ca.sup.+2 or N(C.sub.2 H.sub.5).sub.2 H.sub.2.sup.+.

Details for Patent 5,039,705

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-09-23